Trade

with

Cytori Therapeutics Inc
(NASDAQ: CYTX)
AdChoices
0.5144
-0.0189
-3.54%
After Hours :
0.4928
-0.0216
-4.20%

Open

0.5500

Previous Close

0.5333

Volume (Avg)

2.27M (836.83k)

Day's Range

0.4900-0.5600

52Wk Range

0.4600-3.93

Market Cap.

40.92M

Dividend Rate ( Yield )

-

Beta

2.44

Shares Outstanding

79.54M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
  • Management effectiveness
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 12.20M

    • Net Income

    • -26.18M

    • Market Cap.

    • 40.92M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -421.90

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 2.44

    • Forward P/E

    • -5.73

    • Price/Sales

    • 4.16

    • Price/Book Value

    • 34.25

    • Price/Cash flow

    • -1.04

      • EBITDA

      • -21.15M

      • Return on Capital %

      • -96.21

      • Return on Equity %

      • -3,056.03

      • Return on Assets %

      • -96.21

      • Book Value/Share

      • 0.02

      • Shares Outstanding

      • 79.54M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Buy
        • 1 Year Price Target

        • 4.25

        • Credit Rating

        • -

        • Analysts

        • 2

        • EPS Estimate

        • 0.01

        • Cashflow Estimate

        • -0.22

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • -43.10

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • 21.92

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 63.54

            • 82.75

            • Pre-Tax Margin

            • -421.90

            • 39.38

            • Net Profit Margin

            • -421.90

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 67.30

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -252.00

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 16.35

              • 0.76

              • Current Ratio

              • 1.23

              • 2.92

              • Quick Ratio

              • 0.88

              • 2.35

              • Interest Coverage

              • -8.24

              • 38.02

              • Leverage Ratio

              • 32.06

              • 2.21

              • Book Value/Share

              • 0.02

              • 4.79

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -0.99

                • 217.39

                • P/E Ratio 5-Year High

                • -18.21

                • 634.30

                • P/E Ratio 5-Year Low

                • -0.88

                • 124.82

                • Price/Sales Ratio

                • 4.16

                • 9.52

                • Price/Book Value

                • 34.25

                • 8.61

                • Price/Cash Flow Ratio

                • -1.04

                • 50.51

                • Key Metrics

                • Company

                  • Shares Short

                    as of -

                  • -

                  • Short Ratio

                    as of -

                  • -

                  • Short % of Float

                    as of -

                  • -

                  • Shares Short

                    prior month

                  • -

                  • Trailing Annual Dividend Yield

                  • -

                  • 5 Year Average Dividend Yield

                  • -

                  • Key Metrics

                  • Company

                    • Payout Ratio

                    • -

                    • Dividend Date

                    • -

                    • Ex-Dividend Date

                    • -

                    • Last Split Factor

                      new per old

                    • -

                    • Last Split Date

                    • -

                    • Key Metrics

                    • Company

                    • Industry

                      • Return on Equity %

                        (5-Year Average)

                      • -3,056.03

                        (-)

                      • 37.63

                        (27.20)

                      • Return on Assets %

                        (5-Year Average)

                      • -96.21

                        (-67.40)

                      • 17.22

                        (13.81)

                      • Return on Capital %

                        (5-Year Average)

                      • -121.61

                        (-)

                      • 21.78

                        (17.31)

                      • Income/Employee

                      • -

                      • 117.08k

                      • Inventory Turnover

                      • 0.76

                      • 1.48

                      • Asset Turnover

                      • 0.23

                      • 0.55

                      Current Historical
                      Financials
                      • Income Statement
                      • Balance Sheet
                      • Cash Flow
                      Operating Income
                      -30.68M
                      Operating Margin
                      -251.55
                      Total Equity
                      -
                      Retained Earnings
                      -
                      Free Cashflow
                      -
                      Price/Cashflow
                      -1.04
                      Ownership

                      Institutional Ownership

                      33.06%

                      Top 10 Institutions

                      27.57%

                      Mutual Fund Ownership

                      6.96%

                      Float

                      87.47%

                      5% / Insider Ownership

                      2.07%

                      Corporate insiders or major stockholders reporting trading activity in the stock.

                      Top Mutual Fund Owners

                      Top Institutional Owners

                      Mutual Fund Name

                      Institution Name

                      • Mutual Fund Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Vanguard Extended Market Index Fund

                      •  

                        1,061,609

                      • 0.00

                      • 1.33

                      • iShares Russell 2000 (AU)

                      •  

                        1,010,137

                      • -1.46

                      • 1.00

                      • Vanguard Total Stock Mkt Idx

                      •  

                        919,452

                      • 0.00

                      • 1.16

                      • iShares Russell 2000 Growth

                      •  

                        315,100

                      • 0.34

                      • 0.31

                      • CREF Stock

                      •  

                        234,658

                      • 0.00

                      • 0.30

                      • Bridgeway Ultra Small Company Market

                      •  

                        200,000

                      • 0.00

                      • 0.25

                      • Fidelity Spartan® Extended Mkt Indx Fd

                      •  

                        195,899

                      • 0.00

                      • 0.25

                      • iShares Micro-Cap

                      •  

                        190,719

                      • 0.00

                      • 0.19

                      • iShares Russell 2000 Value

                      •  

                        145,722

                      • 0.26

                      • 0.14

                      • Vanguard Instl Total Stock Market Index

                      •  

                        139,519

                      • 0.00

                      • 0.18

                      • Institution Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • BlackRock Fund Advisors

                      •  

                        2,496,477

                      • +2.61%

                      • 3.14

                      • Vanguard Group, Inc.

                      •  

                        2,345,766

                      • +3.06%

                      • 2.95

                      • Goldman Capital Management Inc

                      •  

                        1,022,288

                      • +171.59%

                      • 1.26

                      • State Street Corp

                      •  

                        898,532

                      • +1.30%

                      • 1.13

                      • Marathon Capital Management LLC

                      •  

                        886,750

                      • +20.98%

                      • 1.11

                      • Perkins Capital Management Inc

                      •  

                        773,329

                      • +29.33%

                      • 0.97

                      • Northern Trust Investments, N.A.

                      •  

                        684,119

                      • -11.52%

                      • 0.86

                      • Princeton Capital Management Inc

                      •  

                        474,805

                      • +6.62%

                      • 0.60

                      Company Profile

                      Sector

                      Healthcare

                      Industry

                      Biotechnology

                      Type

                      Slow Growth

                      Style

                      Small Core

                      Cytori Therapeutics Inc was incorporated in the State of Delaware in May 1997. The Company is engaged in the development of novel treatments for cardiovascular disease and soft tissue injuries and burns. Its core product is the Celu...moretion System, which extracts the naturally occurring ADRCs from a patient’s own fat tissue and is CE Marked for a range of soft tissue procedures, including breast reconstruction. The company has completed three clinical trials using the Celution System for breast reconstruction, pipeline applications acute myocardial infarction, and chronic myocardial ischemia. It is involved in the European ADVANCE trial for acute myocardial infarction; and the U.S. trial for chronic myocardial ischemia. The company also sells StemSource cell banking line, including cell and tissue bank...moreing lines, as well as the Puregraft System that optimizes the fat graft preparation process. Its therapeutic areas comprises of cardiovascular disease, specifically refractory heart failure due to chronic myocardial ischemia, and the treatment of thermal burns. Its customers in Japan consist of researchers at academic hospitals and clinics. It also has a network of distributors who offer Celution Systems, instrumentation and consumables and Puregraft System to surgeons and hospitals throughout Europe. Celution Systems are or will be subject to stringent government regulation in the United States by the FDA under the Federal Food, Drug and Cosmetic Act.lessless

                      Key People

                      Dr. Marc H. Hedrick,M.D.

                      President/Director/CEO

                      David M. Rickey

                      Director/Chairman of the Board

                      Tiago Girao

                      CFO/Vice President, Divisional

                      Steven Kesten

                      Executive VP/Chief Medical Officer

                      Dr. E. Carmack Holmes,M.D.

                      Director

                      • Cytori Therapeutics Inc

                      • 3020 Callan Road

                      • San Diego, CA 92121

                      • USA.Map

                      • Phone: +1 858 458-0900

                      • Fax: +1 858 458-0994

                      • cytori.com

                      Incorporated

                      1997

                      Employees

                      115

                      Send Feedback

                      We appreciate your input!

                      • I'm having trouble signing into my Microsoft account

                      • I’m having problems with the services stripe (Mail, Facebook, etc.)

                      • There is an issue with my weather information

                      • I see an error in the content

                      • Other

                      Please give an overall site rating: